This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Oncology Podcasts

ESMO 2025

Quick Data Digest Podcast Series on Prostate Cancer Awareness

ESMO 2025 Website Banner

Welcome to our dedicated 

ESMO 2025 
‘quick data digest’ podcast series, where we present exclusive insights from leading oncologists on the latest data released in prostate cancer treatment, filmed at the ESMO Congress in Berlin 2025.

Featuring:

    Dr. John McGrane has been working as a consultant clinical oncologist at the Royal Cornwall Hospital since 2014. He serves as the clinical lead for radiotherapy at the Royal Cornwall Hospital and specializes in radiotherapy and systemic anti-cancer treatment for urological and gynecological cancers.

    In addition to his clinical practice, Dr. McGrane is actively involved in recruiting participants for clinical trials in the fields of urological and gynecological cancers at the Royal Cornwall Hospital. He holds the position of UK Chief Investigator in the IMReal urothelial immunotherapy study and oversees several urological and gynecological trials as Principal Investigator for over 25 clinical trials.

    Dr. McGrane is a co-founder of the UK Renal Oncology Collaboration, which focuses on Real World Evidence in renal cancer. He is also a member of the UK Renal Oncology Group and is dedicated to enhancing the profile of renal cancer and encouraging participation in clinical trials.

    Additionally, Dr. McGrane has a keen interest in digital health solutions for cancer patient follow-up and care. In 2018, he co-founded the award-winning MySunrise cancer patient support app, which is currently active throughout the South West and West Midlands.

    Dr. Kenrick Ng is a Consultant in Medical Oncology and Clinical Director for Inpatient Care at Barts Cancer Centre, St Bartholomew’s Hospital. He is also Editor-in-chief of the journal Oncology and Therapy. He obtained his medical degree from the University of Cambridge in 2012, further to completing a PhD in Tumour Immunology between 2018-2021 in the UCL Cancer Institute under a Cancer Research UK Clinical Research Training Fellowship.

    He is currently tumour group lead for prostate cancer in Barts Cancer Centre, London and UK chief investigator and principal investigator for several early and late phase trials in prostate cancer.

    He has also received research grants from the UK Medical Research Council, Prostate Cancer Research, Cancer Research UK Early Detection Scheme and the Cancer Research UK Cancer Development Fund. He has published more than 70 peer-reviewed articles and book chapters. His research work in prostate cancer has been awarded with the Helen Patterson Research Registrar Award and ASCO Conquer Cancer Foundation Merit Award.

Join Dr. McGrane and Dr. Ng where they delve into the latest advancements in the treatment of prostate cancer as was presented at the ESMO Congress 2025

In this episode,

Dr. McGrane
and
Dr. Ng
present key findings from the ARANOTE post hoc analysis:

Darolutamide efficacy, quality of life, and safety outcomes by age subgroup, released at ESMO 2025.

Dr. McGrane and Dr. Ng also delve into other breaking studies, like AMPLITUDE, a phase III trial of niraparib in mHSPC patients with homologous recombination repair.

NUBEQA® (darolutamide)
ARANOTE – Clinical trial
PP-NUB-GB-2542, August 2025
NUBEQA® (darolutamide) Resources
PP-NUB-GB-2048, February 2025
ASCO GU 2025
NUBEQA® (darolutamide)
PP-NUB-GB-2229, March 2025

PP-NUB-GB-2700 | October 2025